DEA: Xylazine Involved in 6,096 Overdose Deaths in 2023

The Drug Enforcement Administration (DEA) has issued a public safety alert highlighting the increasing prevalence of xylazine in the illicit drug supply. According to CDC data cited by the DEA, xylazine was implicated in 6,096 overdose deaths in 2023, positioning it as the fourth most common drug involved in these fatalities. The alert further notes that xylazine has now been reported in all 50 states, underscoring its widespread distribution.

This notice serves as a critical alert to public health officials, healthcare providers, and law enforcement regarding the significant and growing threat posed by xylazine. While this is an informational notice and not a regulatory rule, it signals a heightened focus on this substance. Regulated entities, particularly those in healthcare and drug distribution, should be aware of these statistics and the potential for increased scrutiny or future regulatory actions concerning xylazine. No specific compliance actions are mandated by this notice, but awareness of the trend is crucial for risk assessment and operational planning.